letrozole vs anastrozole

[Keep it beefy]

can i get a comparison of how powerful these are in comparison to eachother? thanks.

-beef

 

[Citruscide]

you'll probably get better responses if you use their trade names (Femera and Arimidex).

Both are aromatase inhibitors, that is they block the conversion of aromatizable steroids to estrogen. (This is different than Nolva which BLOCKS the estrogen receptors).

It is my believe that most Arimidex comes in .25mg tabs and Femera comes in 2.5mg tabs. As for Arimidex... .5mg/daily will be more than enough to block the effects of estrogen with moderate testosterone use... it might even cause TOO much blockage even... which is why you need to get a blood test taken one week after you start it so you can determine the correct dosage.

Femera.. .on the other hand, is probably MORE potent at BLOCKING estrogen... and comes in 2.5mg tabs... for this reason, you might be able to use 1/2 of a tab every other day, or 1/4 tab every day....

Both Femera and Arimidex are expensive, around the same price for that matter... so for potency and the buck... Femera is your "anti-e" of choice...

you must be careful not to block TOO much estrogen... as you doooo need some.

C-ditty -- hope that helps you

 

[Keep it beefy]

hey thanks a lot. i'm aware of what they do, i'm basically just looking for the most bang for the buck arimidex is so friggin expensive that i was contemplating going this next test cycle without anti-e's and suffering the moon face. but now that i hear femara works, hell i'll just use that, it's significantly cheaper where i've been looking. thanks again!

-beef

 

[Keep it beefy]

one other thing

so when i last did liquidex, i used 1 mg ed, and had some water retention, though not much. are you saying that say, 2.5 mg's of femera every other day would probably be even more potent? if so, femera is less than half the price of the liquidex per effective dose. so, who would ever use arimidex? thanks

-beef

 

[Zyglamail]

I have posted tons of info on most of the anti-e's, here is one comparison.

Femara (Letrozole) More Effective Than Arimidex (Anastrozole) at Inhibiting Estrogen in Advanced Breast Cancer

EAST HANOVER, NJ -- January 31, 2002 -- Data from a randomized study examining the ability of Femara® (letrozole) to inhibit total body aromatization and suppress plasma estrogen levels in 12 postmenopausal women with metastatic breast cancer compared to Arimidex® (anastrozole) have been published in the February 2002 issue of the Journal of Clinical Oncology.
The data show that Femara (2.5 mg once daily) more effectively inhibits total body aromatization and suppresses plasma estrogen levels compared to anastrozole (1 mg once daily). The differences between the two drugs in inhibiting total body aromatization (ovaries excepted) were statistically significant as was the suppression of two of the three major estrogens.
"We know that hormone sensitive breast cancers rely on estrogen for growth, and in this study, Femara was shown to be a more effective inhibitor of total body aromatization and suppressor of plasma estrogen levels as compared to anastrozole," said Per Eystein Lonning, MD, professor of oncology, Haukeland University Hospital, Norway.

The primary objective of the study was to compare the effects of the non-steroidal aromatase inhibitors Femara and anastrozole on total body aromatization (the capacity of the whole body to produce estrogens) and plasma estrogen levels.

The trial was a randomized, crossover study of 12 postmenopausal women with metastatic breast cancer whose disease was suitable for treatment with an aromatase inhibitor. Patients were treated sequentially with anastrozole 1 mg followed by Femara 2.5 mg once daily (and vice-versa), each given for six weeks in sequence. Total body aromatization was determined prior to treatment and at the end of each treatment period as were plasma levels of estrone (E1), estradiol (E2) and estrone sulfate (E1S).

The study revealed that whereas on-treatment levels of aromatization were detectable in 11 of 12 patients during treatment with anastrozole (mean percentage inhibition in the whole group 97.3 percent), they were undetectable in all of the 12 patients during treatment with Femara (> 99.1 percent suppression in all patients; Wilcoxon, P = .0022, comparing the two drug regimens).

Treatment with Femara as compared to anastrozole suppressed mean plasma estrogen levels as follows: E1 (84.3 percent versus 81.0 percent), E1S (98.0 percent versus 93.5 percent) and E2 (87.8 percent versus 84.9 percent) respectively. The suppression of plasma levels of E1 and E1S also was found to be better during treatment with Femara compared to anastrozole (P= .019 and P= .0037, respectively). Since the levels of E2 are already very low in postmenopausal women, it was not possible to measure a statistically significant difference for this parameter.

Based on these findings, the authors concluded that Femara is a more effective inhibitor of total body aromatization and suppressor of plasma estrogen levels compared to anastrozole in postmenopausal women with metastatic breast cancer. The clinical relevance of this finding is yet to be determined.

Femara, an aromatase inhibitor, is an oral once-a-day first-line treatment for postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer. At the 2001 San Antonio Breast Cancer Symposium, Phase III data were presented demonstrating that Femara may improve survival of postmenopausal women with locally advanced or metastatic breast cancer who are appropriate for hormone therapy, when compared to tamoxifen. The data stemmed from the largest single study ever to evaluate a hormonal therapy in advanced breast cancer.

The U.S. Food and Drug Administration (FDA) approved Femara in the first-line indication in January 2001. Femara is currently available in more than 75 countries worldwide, with first-line approval already gained in more than 50 countries.

Femara is contraindicated in patients with known hypersensitivity to Femara or any of its excipients. Femara is generally well tolerated and adverse reactions rates in the first-line study in which Femara was compared to tamoxifen were similar with those seen in second-line studies.

The most commonly reported adverse events for Femara versus tamoxifen were bone pain (20 percent versus 18 percent), hot flushes (18 percent versus 15 percent), back pain (17 percent versus 17 percent), nausea (15 percent versus 16 percent), dyspnea or labored breathing (14 percent versus 15 percent), arthralgia (14 percent versus 13 percent), fatigue (11 percent versus 11 percent), coughing (11 percent versus 10 percent), constipation (9 percent versus 9 percent), chest pain (8 percent versus 8 percent) and headache (8 percent versus 7 percent).

Femara may cause fetal harm when administered to pregnant women. The incidence of peripheral thromoembolic events, cardiovascular events and cerebrovascular events was less than or equal to 2 percent. There is no clinical experience to date on the use of Femara in combination with other anticancer agents.

Here is a link to a thread that has extensive abstracts and will keep you busy for a while.

http://boards.elitefitness.com/forum/showthread.php?s=&threadid=150922&highlight=aromasin+letrozole

 

[georgie24]

anybody mess with letro from?

 

[HUCKLEBERRY FINNaplex]

Both femara and liquidex worked about the same for me and my training partner.We loved them both.

 

[Citruscide]

I'm really astonished at the frequency that questions are asked and "re-asked" on a daily basis.. LOL

C-ditty

 

[tbro]

exemestane is better in some bodybuilding arenas and not others why?

 

[HUCKLEBERRY FINNaplex]

exemestane is better in some bodybuilding arenas and not others why?

Individualistic genetic response.Varies greatly from person to person.Most people respond much better to letrozole than liquidex/anastrozole,for me they feel about the same.

 

[tbro]

thanks huck